Personalized briefing
Discovery of the day · Neurology
Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer’s disease progression
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Alzheimer’s Disease Biomarkers
Discovery of the day
This multi-cohort study of 2,117 individuals establishes that baseline plasma p-tau217 thresholds achieve high and sustained accuracy (86–95%) for Aβ-PET positivity over up to 5 years of follow-up, demonstrating the diagnostic robustness of this blood-based proteomic biomarker. Longitudinally, 93–98% of p-tau217–positive individuals remained stable, while those in the intermediate zone progressed to positive at substantially higher rates (44–78%) than negative individuals (4–21%), with stable-positive and progress-to-positive profiles exhibiting accelerated tau accumulation and hippocampal atrophy. These findings support plasma p-tau217 monitoring as a clinically actionable, scalable tool for Alzheimer’s disease risk stratification and disease monitoring, directly advancing the integration of blood-based proteomic biomarkers into multimodal diagnostic workflows alongside imaging and clinical data.
Novelty
94%
Rigor
89%
Significance
92%
Validity
90%
Clarity
93%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
